Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
linvoseltamab + dupilumab
- Development stage
- Phase 1
- Lead developer
- Regeneron Pharmaceuticals
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
**Linvoseltamab + dupilumab** is a combination of two monoclonal antibodies studied for the treatment of severe IgE-mediated food allergy. **Linvoseltamab** targets B-cell maturation antigen (BCMA) to modulate abnormal B-cell activity, while **dupilumab** blocks interleukin-4 receptor alpha, suppressing signaling of IL-4 and IL-13, key cytokines responsible for type 2 inflammation. This dual approach seeks to diminish both the hypersensitivity immune reaction (through modulation of plasma cells and B-cell function) and the downstream inflammatory processes typical of allergic conditions. Both drugs are developed by Regeneron Pharmaceuticals. Dupilumab is already approved for several inflammatory indications, including atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis, whereas linvoseltamab is investigational in this combination and in other contexts, such as multiple myeloma[1][2][4][5].
- Brand names
- DUPIXENT (dupilumab)
- Other names
- linvoseltamab + dupilumab
02
Targets
BCMA (B-cell maturation antigen)CD3 (T-cell surface glycoprotein CD3)IL4R (Interleukin-4 receptor alpha subunit)IL13RA2 (Interleukin-13 receptor subunit alpha 2)
Beyond the preview
Go deeper on linvoseltamab + dupilumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on linvoseltamab + dupilumab.